Phase 3
Completed N=35
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Source: ClinicalTrials.gov NCT05718466 ↗
Enrolled (actual)
35
Serious AEs
25.7%
Results posted
Jul 2023
Primary outcomePrimary: Local Tumor Control — 14; 4 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Local Tumor Control |
14; 4 | — |
| PRIMARY Overall Survival |
7.2; 4.8 | 0.11 |
| PRIMARY Progression Free Survival |
5.1; 1.8 | 0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Histologically proven intracranial glioblastoma multiforme with pathologic or imaging confirmation of tumor progression or regrowth after failure of two previous treatment regimens
- Initial low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma
- History and physical exam, including neurologic examination, within 4 weeks prior to registration
Exclusion Criteria
- Warfarin or LMW heparin patients must have no active bleeding or pathological condition that carries a high risk of bleeding
Data sourced from ClinicalTrials.gov (NCT05718466). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.